Paul Tudor Jones's VRTX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 30,176 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $14.99 M, representing 0.02% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 37 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 51,374 shares. Largest reduction occurred in Q4 2025, reducing 45,733 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +30,176 | New Buy | 30,176 | $496.73 |
| Q1 2026 | -5,641 | Sold Out | 0 | $0.00 |
| Q4 2025 | -45,733 | Reduce 89.02% | 5,641 | $453.36 |
| Q3 2025 | +51,374 | New Buy | 51,374 | $391.64 |
| Q1 2025 | -9,463 | Sold Out | 0 | $0.00 |
| Q4 2024 | +9,463 | New Buy | 9,463 | $402.70 |
| Q2 2024 | -23,529 | Sold Out | 0 | $0.00 |
| Q1 2024 | -2,876 | Reduce 10.89% | 23,529 | $418.01 |
| Q4 2023 | -6,950 | Reduce 20.84% | 26,405 | $406.89 |
| Q3 2023 | +33,355 | New Buy | 33,355 | $347.74 |
| Q1 2023 | -7,580 | Sold Out | 0 | $0.00 |
| Q4 2022 | +7,580 | New Buy | 7,580 | $0.29 |
| Q4 2021 | -29,658 | Sold Out | 0 | $0.00 |
| Q3 2021 | +29,658 | New Buy | 29,658 | $181.40 |
| Q2 2021 | -17,262 | Sold Out | 0 | $0.00 |
| Q1 2021 | -29,041 | Reduce 62.72% | 17,262 | $214.87 |
| Q4 2020 | +40,600 | Add 711.91% | 46,303 | $236.33 |
| Q3 2020 | -2,084 | Reduce 26.76% | 5,703 | $272.14 |
| Q2 2020 | -2,585 | Reduce 24.92% | 7,787 | $290.36 |
| Q1 2020 | -5,276 | Reduce 33.72% | 10,372 | $237.95 |
| Q4 2019 | +15,648 | New Buy | 15,648 | $218.94 |
| Q1 2019 | -6,359 | Sold Out | 0 | $0.00 |
| Q4 2018 | -1,943 | Reduce 23.40% | 6,359 | $165.75 |
| Q3 2018 | -9,286 | Reduce 52.80% | 8,302 | $192.72 |
| Q2 2018 | +15,157 | Add 623.49% | 17,588 | $169.95 |
| Q1 2018 | -7,985 | Reduce 76.66% | 2,431 | $162.90 |
| Q4 2017 | +10,416 | New Buy | 10,416 | $149.87 |
| Q1 2017 | -9,611 | Sold Out | 0 | $0.00 |
| Q4 2016 | +9,611 | New Buy | 9,611 | $73.67 |
| Q1 2016 | -6,286 | Sold Out | 0 | $0.00 |
| Q4 2015 | +6,286 | New Buy | 6,286 | $125.84 |
| Q3 2015 | -2,729 | Sold Out | 0 | $0.00 |
| Q2 2015 | +2,729 | New Buy | 2,729 | $123.49 |
| Q1 2015 | -6,589 | Sold Out | 0 | $0.00 |
| Q4 2014 | -1,137 | Reduce 14.72% | 6,589 | $118.83 |
| Q3 2014 | +5,548 | Add 254.73% | 7,726 | $112.35 |
| Q2 2014 | +2,178 | New Buy | 2,178 | $94.58 |
Paul Tudor Jones's Vertex Pharmaceuticals Incorporated Investment FAQs
Paul Tudor Jones first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q2 2014, acquiring 2,178 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Vertex Pharmaceuticals Incorporated (VRTX) for 37 quarters since Q2 2014.
Paul Tudor Jones's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q3 2025, adding 51,374 shares worth $20.12 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 30,176 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $14.99 M.
As of the Q2 2026 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 51,374 shares, as reported at the end of Q3 2025.